Other metastatic colorectal cancers, such as microsatellite-stable cases and those with alterations in other pathways besides receptor tyrosine kinases/KRAS/BRAF, have fewer targeted options and are treated with cytotoxic chemotherapies or anti-angiogenic therapies [7,8]. This evidence concerns the gene BRAF and metastatic colorectal cancer.